[Special Stock] NatureCell Hits Upper Limit for Two Consecutive Days Following US FDA 'Breakthrough Therapy' Designation

Naturecell's degenerative arthritis cell gene therapy 'Jointstem' has been soaring for the second day following its designation as a breakthrough therapy by the U.S. Food and Drug Administration (FDA).

As of 9:30 a.m. on the 25th, Naturecell's stock price rose 5,350 KRW (24.10%) from the previous day to 27,550 KRW.

During the trading session, it reached 28,550 KRW, continuing its sharp rise for the second consecutive day following the previous day's limit-up.

The news that Naturecell's Jointstem was designated as a breakthrough therapy by the U.S. FDA is believed to be driving the stock price upward.

Earlier, on the 21st, Naturecell announced that Jointstem had been designated as a breakthrough therapy by the U.S. FDA in the field of cell therapy.

Jointstem is an autologous adipose-derived mesenchymal stem cell therapy. According to the company, it is administered via local injection into the knee joint cavity, inducing cartilage regeneration, and can sustain pain reduction and joint function improvement effects for at least three years.